Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Freegold Intersects 1.53 g/t Au over 191.3m in infill drilling at Golden Summit (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Myriad Genetics Inc MYGN

Healthcare Diagnostics & Research
Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops and provides molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:MYGN)

Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health

GlobeNewswire 9 days ago

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

GlobeNewswire November 11, 2025

Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs

GlobeNewswire November 10, 2025

Myriad Genetics to Highlight Genetic Testing Advancements at 2025 National Society of Genetic Counselors Annual Conference

GlobeNewswire November 6, 2025

Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution

GlobeNewswire November 3, 2025

New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner

GlobeNewswire October 31, 2025

Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025

GlobeNewswire October 27, 2025

Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel

GlobeNewswire October 14, 2025

Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy

Canada NewsWire September 23, 2025
View More News ››

Opinion & Analysis (NDAQ:MYGN)

Myriad Genetics Shares Fall 30% on Q2 Earnings and Executive Leadership Change

Streetwise Reports February 10, 2020

This company's loss is your gain

Marc Lichtenfeld June 19, 2013

Stock pick in cancer genetics testing

Michael Cintolo December 23, 2008
View More Opinion ››

Bullboard Posts (NDAQ:MYGN)

4 STOCKS OPENING NEW FRONTIERS IN WOMEN’S HEALTH!

$MYGN $SERA $PGNY $MYOV   8th March celebrates the cultural, political and socioeconomic achievements of women ...
AviseAnalytics - March 8, 2022

Myriad Genetics Inc. Options

On 01/12/09 Myriad Genetics Inc. options ( MYGN ) are used as an example of market neutral investing on PERSONALHEDGEFUNDS.COM. Hedge...
nickmessaro02 - January 10, 2009

MYGN is seen possible buy by Chartplays.com

MYGN is reviewed as the focus free chart of the day at Chartplays.com today. According to the folks at Chartplays.com, MYGN is showing...
battlinal74 - August 16, 2002

Target Acquire Price $16

Anyone have any opinions? Great balance sheet, but drastically overpriced.
0379 - May 7, 2002

Genomics Execs Aren’t Worried

Ignore the bears, genomics bulls say. Advancements in medicine are coming and companies that understand genes are the ones that will make...
SCCNewsServices - April 17, 2000
View more Bullboard ››

Sorrento Resources Ltd.

Sorrento Resources Ltd.

Sorrento is engaged in acquisition, exploration, and development of mineral property assets in Canada. Sorrento’s objective ...
View More »